Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) EBITDA (2020 - 2026)

Maxcyte has reported EBITDA over the past 6 years, most recently at $32.4 million for Q4 2025.

  • Quarterly EBITDA rose 5.15% to $32.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6.2 million through Dec 2025, down 14.72% year-over-year, with the annual reading at -$5.1 million for FY2025, 19.14% down from the prior year.
  • EBITDA was $32.4 million for Q4 2025 at Maxcyte, up from -$13.1 million in the prior quarter.
  • Over five years, EBITDA peaked at $32.4 million in Q4 2025 and troughed at -$14.0 million in Q3 2023.
  • The 5-year median for EBITDA is -$8.2 million (2022), against an average of -$2.5 million.
  • The largest YoY upside for EBITDA was 577.57% in 2023 against a maximum downside of 216.85% in 2023.
  • A 5-year view of EBITDA shows it stood at $9.2 million in 2021, then crashed by 173.17% to -$6.8 million in 2022, then skyrocketed by 577.57% to $32.2 million in 2023, then decreased by 4.56% to $30.8 million in 2024, then grew by 5.15% to $32.4 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's EBITDA are $32.4 million (Q4 2025), -$13.1 million (Q3 2025), and -$13.1 million (Q2 2025).